Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors

Molecular Pharmacology

Volumn 81, Issue 6, 2012, Pages 832-845

  Schepetkin, Igor A ^a   Kirpotina, Liliya N ^a   Khlebnikov, Andrei I ^b   Hanks, Tracey S ^a   Kochetkova, Irina ^a   Pascual, David W ^a   Jutila, Mark A ^a   Quinn, Mark T ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b ALTAI STATE TECHNICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

11H INDENO[1,2 B]QUINOXALIN 11 ON O(2 FUROYL)OXIME; 11H INDENO[1,2 B]QUINOXALIN 11 ON OXIME; 11H INDENO[1,2 B]QUINOXALIN 11 ON OXIME SODIUM; 4 [1 CYCLOHEXYL 4 (4 FLUOROPHENYL) 1H IMIDAZOL 5 YL] 2 PYRIMIDINAMINE DIHYDROCHLORIDE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 10; NITRIC OXIDE; OVALBUMIN; PF 670462; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG IDENTIFICATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VIVO STUDY; MACROPHAGE; MOLECULAR DOCKING; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGEN BONDING; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS;

EID: 84861437451     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.077446     Document Type: Article

References (79)

1. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, et al. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5:995-1006. (Pubitemid 43724600)
2. Atreya I, Atreya R, and Neurath MF (2008) NF-κB in inflammatory bowel disease. J Intern Med 263:591-596.
3. Bain J, McLauchlan H, Elliott M, and Cohen P (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371:199-204. (Pubitemid 36458094)
4. Bała M, Michańków M, Chojnacka-Wójcik E, Wiczyńska B, and Tatarczyńska E (1983) Chemistry and anti-inflammatory activity of 10-methylamino-11H-indeno-[1,2-b]quinolin-11-one (MB 432) derivatives. Pol J Pharmacol Pharm 35:523-530.
5. Bała M, Naparzewska A, and Chojnacka-Wójcik E (1986) Analgesic and antiinflammatory activity of 10-amino-11H-indeno-[1,2-b]quinolin- 11-one derivatives. Pol J Pharmacol Pharm 38:221-227.
6. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686. (Pubitemid 33115958)
7. Bennett BL, Satoh Y, and Lewis AJ (2003) JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 3:420-425. (Pubitemid 36908946)
8. Bhagwat SS (2007) MAP kinase inhibitors in inflammation and autoimmune disorders. Annu Rep Med Chem 42:265-278.
9. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, and Barr RK (2004) Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 1697:89-101. (Pubitemid 38326764)
10. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, and Ng DC (2010) c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 1804:463-475.
11. 2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther 310:25-32.
12. Chambers JW, Pachori A, Howard S, Ganno M, Hansen D Jr, Kamenecka T, Song X, Duckett D, Chen W, Ling YY, et al. (2011) Small molecule c-Jun-N-terminal kinase (JNK) inhibitors protect dopaminergic neurons in a model of parkinson's disease. ACS Chem Neurosci 2:198-206.
13. Chen CY, Gherzi R, Andersen JS, Gaietta G, Jürchott K, Royer HD, Mann M, and Karin M (2000) Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev 14:1236-1248. (Pubitemid 30327504)
14. Chialda L, Zhang M, Brune K, and Pahl A (2005) Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. Respir Res 6:36.
15. Chojnacka-Wójcik E and Naparzewska A (1983) Pharmacological properties of the antiinflammatory agent 10-methylamine-11-H-indeno-[1,2-b] quinolin-11-one (MB432). Pol J Pharmacol Pharm 35:327-332.
16. Christopher JA, Atkinson FL, Bax BD, Brown MJ, Champigny AC, Chuang TT, Jones EJ, Mosley JE, and Musgrave JR (2009) 1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3. Bioorg Med Chem Lett 19:2230-2234.
17. Das M, Garlick DS, Greiner DL, and Davis RJ (2011) The role of JNK in the development of hepatocellular carcinoma. Genes Dev 25:634-645.
18. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
19. Deady LW, Desneves J, Kaye AJ, Thompson M, Finlay GJ, Baguley BC, and Denny WA (1999) Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6- carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA. Bioorg Med Chem 7:2801-2809. (Pubitemid 30105852)
20. Deady LW, Kaye AJ, Finlay GJ, Baguley BC, and Denny WA (1997) Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem 40:2040-2046. (Pubitemid 27265980)
21. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336. (Pubitemid 41094421)
22. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, and Chiao PJ (2004) NF-κB and AP-1 connection: mechanism of NF-κB-dependent regulation of AP-1 activity. Mol Cell Biol 24:7806-7819. (Pubitemid 39121503)
23. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D, et al. (2005) Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem 48:4596-4607. (Pubitemid 40993420)
24. Ghalib RM, Hashim R, Sulaiman O, Hemamalini M, and Fun HK (2010) 11H-indeno-[1,2-b]quinoxalin-11-one. Acta Crystallogr Sect E Struct Rep Online 66:o1494.
25. Ghosh S and Hayden MS (2008) New regulators of NF-κB in inflammation. Nat Rev Immunol 8:837-848.
26. Gupta SC, Sundaram C, Reuter S, and Aggarwal BB (2010) Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799:775-787.
27. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, and Firestein GS (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73-81. (Pubitemid 32634924)
28. Harbecke O, Dahlgren C, Bergman J, and Möller L (1999) The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b) quinoxaline inhibits neutrophil production of reactive oxygen species. J Leukoc Biol 65:771-777. (Pubitemid 29279525)
29. He Y, Kamenecka TM, Shin Y, Song X, Jiang R, Noel R, Duckett D, Chen W, Ling YY, Cameron MD, et al. (2011) Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett 21:1719-1723.
30. Hibi M, Lin A, Smeal T, Minden A, and Karin M (1993) Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135-2148. (Pubitemid 23336140)
31. Hultqvist M, Nandakumar KS, Björklund U, and Holmdahl R (2010) Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann Rheum Dis 69:1527-1532.
32. Jester BW, Cox KJ, Gaj A, Shomin CD, Porter JR, and Ghosh I (2010) A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. J Am Chem Soc 132:11727-11735.
33. Johnson GL and Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912. (Pubitemid 35425238)
34. Jung DH, Park HJ, Byun HE, Park YM, Kim TW, Kim BO, Um SH, and Pyo S (2010) Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF-κB and AP-1 activation. Int Immunopharmacol 10: 1047-1054.
35. Kalia J and Raines RT (2008) Hydrolytic stability of hydrazones and oximes. Angew Chem Int Ed Engl 47:7523-7526.
36. Kamenecka T, Habel J, Duckett D, Chen W, Ling YY, Frackowiak B, Jiang R, Shin Y, Song X, and LoGrasso P (2009) Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38. J Biol Chem 284:12853-12861.
37. Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, and Colburn NH (2009) A selective small-molecule nuclear factor-κB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits". Mol Cancer Ther 8:571-581.
38. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
39. Kikkert R, de Groot ER, and Aarden LA (2008) Cytokine induction by pyrogens: comparison of whole blood, mononuclear cells, and TLR-transfectants. J Immunol Methods 336:45-55.
40. Kirpotina LN, Khlebnikov AI, Schepetkin IA, Ye RD, Rabiet MJ, Jutila MA, and Quinn MT (2010) Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol 77:159-170.
41. + regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184:7144-7153.
42. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer TW, Spitzer GM, et al. (2011) Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One 6:e23852.
43. Law M, Corsino P, Parker NT, and Law BK (2010) Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-κB using in silico molecular docking. Cancer Lett 291:217-224.
44. Mehan S, Meena H, Sharma D, and Sankhla R (2011) JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J Mol Neurosci 43:376-390.
45. Melino M, Hii CS, McColl SR, and Ferrante A (2008) The effect of the JNK inhibitor, JIP peptide, on human T lymphocyte proliferation and cytokine production. J Immunol 181:7300-7306.
46. Moreau A, Le Vee M, Jouan E, Parmentier Y, and Fardel O (2011) Drug transporter expression in human macrophages. Fundam Clin Pharmacol 25:743-752.
47. Nijboer CH, van der Kooij MA, van Bel F, Ohl F, Heijnen CJ, and Kavelaars A (2010) Inhibition of the JNK/AP-1 pathway reduces neuronal death and improves behavioral outcome after neonatal hypoxic-ischemic brain injury. Brain Behav Immun 24:812-821.
48. 4 solution. Mater Chem Phys 122:325-328.
49. Oh KS, Lee S, Choi JK, and Lee BH (2010) Identification of novel scaffolds for IkB kinase beta inhibitor via a high-throughput screening TR-FRET assay. Comb Chem High Throughput Screen 13:790-797.
50. Pearson BD (1962) Indenoquinolines. III. Derivatives of 11H-indeno-[1,2-b]quinoxaline and related indenoquinolines. J Org Chem 27:1674-1678.
51. Peddibhotla S, Shi R, Khan P, Smith LH, Mangravita-Novo A, Vicchiarelli M, Su Y, Okolotowicz KJ, Cashman JR, Reed JC, et al. (2010) Inhibition of protein kinase C-driven nuclear factor-κB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. J Med Chem 53:4793-4797.
52. Peng SL (2008) Transcription factors in autoimmune diseases. Front Biosci 13:4218-4240.
53. Perez DI, Gil C, and Martinez A (2011) Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev 31:924-954.
54. Plantevin Krenitsky V, Nadolny L, Delgado M, Ayala L, Clareen SS, Hilgraf R, Albers R, Hegde S, D'Sidocky N, Sapienza J, et al. (2012) Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 22:1433-1438.
55. Posy SL, Hermsmeier MA, Vaccaro W, Ott KH, Todderud G, Lippy JS, Trainor GL, Loughney DA, and Johnson SR (2011) Trends in kinase selectivity: insights for target class-focused library screening. J Med Chem 54:54-66.
56. Rajasekaran A (2007) Synthesis, antinociceptive, antiinflammatory and antiepileptic evaluation of some novel indeno[1,2-b]quinoxalin-11-ylidenamines. Iran J Pharm Sci 3:251-262.
57. Resnick L and Fennell M (2004) Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov Today 9:932-939. (Pubitemid 39389054)
58. Sabapathy K, Hu Y, Kallunki T, Schreiber M, David JP, Jochum W, Wagner EF, and Karin M (1999) JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr Biol 9:116-125. (Pubitemid 29087541)
59. Schepetkin IA, Khlebnikov AI, Kirpotina LN, and Quinn MT (2006) Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem 49:5232-5244. (Pubitemid 44260219)
60. Schepetkin IA, Khlebnikov AI, and Quinn MT (2007a) N-Benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem 50:4928-4938. (Pubitemid 47525476)
61. Schepetkin IA, Kirpotina LN, Jakiw L, Khlebnikov AI, Blaskovich CL, Jutila MA, and Quinn MT (2009) Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium. J Immunol 183:6754-6766.
62. Schepetkin IA, Kirpotina LN, Khlebnikov AI, and Quinn MT (2007b) High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Mol Pharmacol 71:1061-1074. (Pubitemid 46457010)
63. Shibinskaya MO, Lyakhov SA, Mazepa AV, Andronati SA, Turov AV, Zholobak NM, and Spivak NY (2010) Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxalines. Eur J Med Chem 45:1237-1243.
64. Shin Y, Chen W, Habel J, Duckett D, Ling YY, Koenig M, He Y, Vojkovsky T, LoGrasso P, and Kamenecka TM (2009) Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett 19: 3344-3347.
65. Skazik C, Heise R, Bostanci O, Paul N, Denecke B, Joussen S, Kiehl K, Merk HF, Zwadlo-Klarwasser G, and Baron JM (2008) Differential expression of influx and efflux transport proteins in human antigen presenting cells. Exp Dermatol 17: 739-747.
66. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ, et al. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem 49:3563-3580. (Pubitemid 43902462)
67. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, and Davis RJ (2000) Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870-874. (Pubitemid 30257738)
68. Vaiopoulos AG, Papachroni KK, and Papavassiliou AG (2010) Colon carcinogenesis: learning from NF-κB and AP-1. Int J Biochem Cell Biol 42:1061-1065.
69. Vallières M and Du Souich P (2010) Modulation of inflammation by chondroitin sulfate. Osteoarthritis Cartilage 18 (Suppl 1):S1-S6.
70. Wagner G and Laufer S (2006) Small molecular anti-cytokine agents. Med Res Rev 26:1-62. (Pubitemid 43994929)
71. Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, and Hurley LH (2006) Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 5:1764-1773. (Pubitemid 44323244)
72. Watanabe M, Nakashima M, Togano T, Higashihara M, Watanabe T, Umezawa K, and Horie R (2008) Identification of the RelA domain responsible for action of a new NF-κB inhibitor DHMEQ. Biochem Biophys Res Commun 376:310-314.
73. Westman E, Thi Ngoc DD, Klareskog L, and Harris HE (2008) Suppressive effects of a quinoxaline-analogue (Rob 803) on pathogenic immune mechanisms in collagen-induced arthritis. Clin Exp Immunol 152:192-199. (Pubitemid 351347564)
74. Xie X, Gu Y, Fox T, Coll JT, Fleming MA, Markland W, Caron PR, Wilson KP, and Su MS (1998) Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. Structure 6:983-991. (Pubitemid 28397920)
75. Xie X, Gu Y, Markland W, Su MS, Caron PR, Fox E, and Wilson KP (2008), inventors; Vertex Pharmaceuticals, assignees. Methods of designing inhibitors for JNK kinases. US Patent number 7,383,135. 3 Jun 2008.
76. Yan C, Kaoud T, Lee S, Dalby KN, and Ren P (2011) Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1. J Phys Chem B 115:1491-1502.
77. 2-terminal kinase inhibitor SP600125 against potassium deprivation-induced apoptosis involves the Akt pathway and inhibition of cell cycle reentry. Neuroscience 159:1135-1147.
78. Zhang GY and Zhang QG (2005) Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants. Expert Opin Investig Drugs 14:1373-1383.
79. 2-terminal kinase mediates interleukin-1b-induced inhibition of lacrimal gland secretion. J Neurochem 96:126-135.